Chapman-Fredricks Jennifer, Blieden Clifford, Sandoval Jose D, Ernani Vinicius, Ikpatt Offiong Francis
*Department of Pathology and Laboratory Medicine, Division of Hematopathology †Department of Pathology and Laboratory Medicine ‡Department of Medicine, University of Miami, Jackson Memorial Hospital, Miami, FL.
Appl Immunohistochem Mol Morphol. 2014 Apr;22(4):317-21. doi: 10.1097/PAI.0b013e3182275c02.
Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a recently described, uncommon form of DLBCL, which has been seen primarily in young men and which presents with advanced disease. The fact that ALK-positive DLBCL is an uncommon diagnosis is likely due to the combined effects of this being an uncommon disease coupled with the challenges in the pathologic identification of this neoplasm. Prompt and accurate identification of this tumor is becoming increasingly important, however, as we enter the era of therapeutic ALK inhibitors, which are currently undergoing study in several clinical trials. Here, we report a case of ALK-positive DLBCL in a 39-year-old male patient who presented with spontaneous tumor lysis syndrome. We review the clinical, morphologic, immunohistochemical, and molecular aspects of this case and of ALK-positive DLBCL in general, with the purpose of bringing to light the existence of this disease and its potential future therapy.
间变性淋巴瘤激酶（ALK）阳性弥漫性大B细胞淋巴瘤（DLBCL）是一种最近才被描述的罕见的DLBCL形式，主要见于年轻男性，且多表现为晚期疾病。ALK阳性DLBCL诊断不常见，这可能是由于该疾病本身罕见，以及在病理上识别这种肿瘤存在挑战这两个因素共同作用的结果。然而，随着我们进入治疗性ALK抑制剂时代（目前正在多项临床试验中进行研究），迅速而准确地识别这种肿瘤变得越来越重要。在此，我们报告一例39岁男性患者的ALK阳性DLBCL病例，该患者出现了自发性肿瘤溶解综合征。我们回顾了该病例以及ALK阳性DLBCL总体的临床、形态学、免疫组化和分子学方面的情况，目的是揭示这种疾病的存在及其潜在的未来治疗方法。
